Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Cidara Therapeutics Inc (CDTX): Are Hedge Funds Right About This Stock?

Page 1 of 2

Concerns over a shift in Fed’s easy monetary policy have hit several hedge funds hard during the third quarter. A number of sectors are in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by more than 14 percentage points between June 25, 2015 and October 30, 2015. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their portfolios in smaller cap stocks. We have been receiving indications that hedge funds were paring back their overall exposure and this is one of the factors behind the recent movements in major indices. In this article, we will take a closer look at hedge fund sentiment towards Cidara Therapeutics Inc (NASDAQ:CDTX).

Is Cidara Therapeutics Inc (NASDAQ:CDTX) a worthy investment right now? Money managers are getting more optimistic. The number of bullish hedge fund bets inched up by 1 recently. CDTX was in 10 hedge funds’ portfolios at the end of September. There were 9 hedge funds in our database with CDTX holdings at the end of the previous quarter. At the end of this article we will also compare CDTX to other stocks including Inventure Foods Inc (NASDAQ:SNAK), EMCORE Corporation (NASDAQ:EMKR), and ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) to get a better sense of its popularity.

Follow Cidara Therapeutics Inc. (NASDAQ:CDTX)
Trade (NASDAQ:CDTX) Now!

If you’d ask most investors, hedge funds are viewed as unimportant, outdated financial tools of years past. While there are over 8,000 funds trading at present, Our researchers hone in on the aristocrats of this club, about 700 funds. It is estimated that this group of investors command bulk of the smart money’s total capital, and by shadowing their matchless stock picks, Insider Monkey has identified various investment strategies that have historically defeated the S&P 500 index. Insider Monkey’s small-cap hedge fund strategy outperformed the S&P 500 index by 12 percentage points a year for a decade in their back tests.

Keeping this in mind, we’re going to take a glance at the new action encompassing Cidara Therapeutics Inc (NASDAQ:CDTX).

What does the smart money think about Cidara Therapeutics Inc (NASDAQ:CDTX)?

At the end of the third quarter, a total of 10 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 11% from one quarter earlier. With hedge funds’ positions undergoing their usual ebb and flow, there exists an “upper tier” of notable hedge fund managers who were increasing their stakes meaningfully (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, RA Capital Management, managed by Peter Kolchinsky, holds the largest position in Cidara Therapeutics Inc (NASDAQ:CDTX). RA Capital Management has a $15 million position in the stock, comprising 2.2% of its 13F portfolio. The second most bullish fund manager is Aisling Capital, managed by Dennis Purcell, which holds a $13 million position; 2.3% of its 13F portfolio is allocated to the company. Remaining members of the smart money that are bullish encompass Joseph Edelman’s Perceptive Advisors, Hal Mintz’s Sabby Capital and Kris Jenner, Gordon Bussard, Graham McPhail’s Rock Springs Capital Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!